<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02639988</url>
  </required_header>
  <id_info>
    <org_study_id>NI15005</org_study_id>
    <nct_id>NCT02639988</nct_id>
  </id_info>
  <brief_title>Impact of Rheumatoid Arthritis on the Course of Type 2 Diabetes During a Longitudinal Follow-up of 5 Years</brief_title>
  <acronym>INSPIRED</acronym>
  <official_title>Impact of Rheumatoid Arthritis on Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Recherche Clinique Paris Descartes Necker Cochin Sainte Anne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether patients with rheumatoid arthritis and type
      2 diabetes experience a more severe disease course compared to control patients with
      osteoarthritis and type 2 diabetes
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2016</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to the addition of a new treatment for type 2 diabetes in months</measure>
    <time_frame>five years</time_frame>
    <description>addition of a new treatment includes insulin requirement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycated haemoglobin (HbA1c) levels in %</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance (HOMA-IR), absolute value</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requesting insulin in %</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with type 2 diabetes-related acute complications in %</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring the addition of a new treatment for type 2 diabetes in %</measure>
    <time_frame>five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with increased glycated haemoglobin (HbA1c) levels between 2 visits in %</measure>
    <time_frame>five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with increased HOMA-IR between 2 visits in %</measure>
    <time_frame>five years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>rheumatoid arthritis and type 2 diabetes</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>osteoarthritis and type 2 diabetes</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients recruited in five rheumatology departments
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients

          -  Adults (&gt;18 years)

          -  Rheumatoid arthritis fulfilling American College of Rheumatology (ACR )1987 or
             European League Against Rheumatism (ACR/EULAR) 2010 classification criteria

          -  Type 2 diabetes (HbA1c ≥6.5% OR fasting glycemia≥7 mmol/l OR glycemia 120 min after 75
             mg glucose ingestion ≥ 11.1 mmol/l OR symptoms of hyperglycemia with glycemia ≥11.1
             mmol/l)

          -  Affiliated to social security system

        Controls

          -  Adults (&gt;18 years) matched for age, sex and BMI with patients with rheumatoid
             arthritis

          -  Osteoarthritis (knee, hip, spine and hand)

          -  Type 2 diabetes with disease duration matched with patients with rheumatoid arthritis

          -  Affiliated to social security system

        Exclusion Criteria:

          -  Patient not able to understand study implication and rules

          -  Patient opposed to participate to the study

          -  Transient diabetes

          -  Gestational diabetes

          -  Secondary diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme Avouac, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jérôme Avouac, MD, PhD</last_name>
    <phone>+33 1 58412563</phone>
    <email>jerome.avouac@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie Fauroux</last_name>
    <phone>+33 1 58 441 12 13</phone>
    <email>valerie.fauroux@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AP-HP, Cochin hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerôme Avouac, MD, PhD</last_name>
      <phone>+33158412563</phone>
      <email>jerome.avouac@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Meune C, Touzé E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010 Apr;103(4):253-61. doi: 10.1016/j.acvd.2010.03.007. Epub 2010 May 18. Review.</citation>
    <PMID>20656636</PMID>
  </reference>
  <reference>
    <citation>Meune C, Touzé E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2009 Oct;48(10):1309-13. doi: 10.1093/rheumatology/kep252. Epub 2009 Aug 20. Review.</citation>
    <PMID>19696061</PMID>
  </reference>
  <reference>
    <citation>Liao KP, Solomon DH. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford). 2013 Jan;52(1):45-52. doi: 10.1093/rheumatology/kes243. Epub 2012 Sep 16. Review.</citation>
    <PMID>22986289</PMID>
  </reference>
  <reference>
    <citation>Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation. 2004 Aug 17;110(7):803-9. Epub 2004 Aug 2.</citation>
    <PMID>15289378</PMID>
  </reference>
  <reference>
    <citation>Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, Sokka T, Raggi P, Pincus T, Stein CM. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008 Jul;58(7):2105-12. doi: 10.1002/art.23600.</citation>
    <PMID>18576352</PMID>
  </reference>
  <reference>
    <citation>Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum. 2006 Sep;54(9):2765-75.</citation>
    <PMID>16947779</PMID>
  </reference>
  <reference>
    <citation>Ashida R, Ihn H, Mimura Y, Jinnin M, Asano Y, Kubo M, Tamaki K. Clinical features of scleroderma patients with contracture of phalanges. Clin Rheumatol. 2007 Aug;26(8):1275-7. Epub 2006 Dec 15.</citation>
    <PMID>17171315</PMID>
  </reference>
  <reference>
    <citation>Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005 May;64(5):765-6. Epub 2004 Sep 30.</citation>
    <PMID>15458960</PMID>
  </reference>
  <reference>
    <citation>Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol. 2007 Mar-Apr;36(2):91-6.</citation>
    <PMID>17476613</PMID>
  </reference>
  <reference>
    <citation>Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011 Jun 22;305(24):2525-31. doi: 10.1001/jama.2011.878.</citation>
    <PMID>21693740</PMID>
  </reference>
  <reference>
    <citation>Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006 Dec 7;355(23):2427-43. Epub 2006 Dec 4. Erratum in: N Engl J Med. 2007 Mar 29;356(13):1387-8.</citation>
    <PMID>17145742</PMID>
  </reference>
  <reference>
    <citation>Arrieta F, Piñera M, Iglesias P, Nogales P, Salinero-Fort MA, Abanades JC, Botella-Carretero JI, Calañas A, Balsa JA, Zamarrón I, Rovira A, Vázquez C; ESD2 Group. Metabolic control and chronic complications during a 3-year follow-up period in a cohort of type 2 diabetic patients attended in primary care in the Community of Madrid (Spain). Endocrinol Nutr. 2014 Jan;61(1):11-7. doi: 10.1016/j.endonu.2013.09.002. Epub 2013 Oct 30.</citation>
    <PMID>24182687</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2015</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

